Avenue Therapeutics schedules Type C FDA meeting for IV Tramadol; appoints MacLean to board, Kranzler Chairman

AVENUE THERAPEUTICS, INC.

Type C FDA meeting on March 9, 2023 to discuss IV Tramadol respiratory depression study protocol; update expected April 2023.
Board expanded to six; CEO Alexandra MacLean appointed director; Jay Kranzler named Chairman, Lindsay Rosenwald remains director.
Annual meeting set for June 22, 2023; record date April 25, 2023; stockholder proposal deadline March 24, 2023.
FDA previously agreed on study design aspects in August 2022 Type A meeting for IV Tramadol.

item 5.02 item 5.08 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jay Kranzler

Chairman of the Board

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2023-03-07
Filed: March 8, 2023, 6:59 PM ET

appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately

Appointed

Alexandra MacLean

Director

ATXI · AVENUE THERAPEUTICS, INC.

Effective: 2023-03-07
Filed: March 8, 2023, 6:59 PM ET

appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jay Kranzler was appointed as Chairman of the Board at AVENUE THERAPEUTICS, INC..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexandra MacLean was appointed as Director at AVENUE THERAPEUTICS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately

View on SEC.gov

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-030103

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.